https://bioutah.org/ratio-therapeutics-closes-70m-series-c-financing/2026-08-06T16:27:13ZBioUtahenRatio Therapeutics Closes $70M Series C Financing2026-08-06T16:27:13ZBloghttps://bioutah.org/dash-bio-raises-30m-series-a-to-accelerate-drug-development-timelines/2026-08-06T16:25:38ZBioUtahenDash Bio Raises $30M Series A to Accelerate Drug Development Timelines2026-08-06T16:25:04ZBloghttps://bioutah.org/co-diagnostics-submits-fda-510k-premarket-notification-for-upper-respiratory-point-of-care-test/2026-08-06T16:21:48ZBioUtahenCo-Diagnostics Submits FDA 510(k) Premarket Notification for Upper Respiratory Point-of-Care Test2026-08-06T16:21:48ZBloghttps://bioutah.org/co-diagnostics-raises-capital-through-warrant-inducement-ahead-of-fda-review/2026-08-06T16:20:28ZBioUtahenCo-Diagnostics Raises Capital Through Warrant Inducement Ahead of FDA Review2026-08-06T16:20:28ZBloghttps://bioutah.org/arup-laboratories-adds-cyclospora-data-to-infectious-disease-dashboard-amid-national-outbreak/2026-08-06T16:17:52ZBioUtahenARUP Laboratories Adds Cyclospora Data to Infectious Disease Dashboard Amid National Outbreak2026-08-06T16:17:11ZBloghttps://bioutah.org/fluidx-medical-closes-financing-to-advance-next-generation-embolic-platform/2026-08-06T15:38:32ZBioUtahenFluidx Medical Closes Financing to Advance Next-Generation Embolic Platform2026-08-06T15:38:32ZBlog